PHAXIAM Therapeutics (PHXM) Competitors $3.10 0.00 (0.00%) As of 09/10/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock PHXM vs. ACRV, OTLK, LVTX, GBIO, PLUR, TELO, XFOR, EGRX, ESLA, and SCYXShould you be buying PHAXIAM Therapeutics stock or one of its competitors? The main competitors of PHAXIAM Therapeutics include Acrivon Therapeutics (ACRV), Oncobiologics (OTLK), LAVA Therapeutics (LVTX), Generation Bio (GBIO), Pluri (PLUR), Telomir Pharmaceuticals (TELO), X4 Pharmaceuticals (XFOR), Eagle Pharmaceuticals (EGRX), Estrella Immunopharma (ESLA), and SCYNEXIS (SCYX). These companies are all part of the "pharmaceutical products" industry. PHAXIAM Therapeutics vs. Its Competitors Acrivon Therapeutics Oncobiologics LAVA Therapeutics Generation Bio Pluri Telomir Pharmaceuticals X4 Pharmaceuticals Eagle Pharmaceuticals Estrella Immunopharma SCYNEXIS Acrivon Therapeutics (NASDAQ:ACRV) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations. Do analysts recommend ACRV or PHXM? Acrivon Therapeutics presently has a consensus price target of $15.50, suggesting a potential upside of 900.00%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Acrivon Therapeutics is more favorable than PHAXIAM Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acrivon Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor ACRV or PHXM? In the previous week, Acrivon Therapeutics had 3 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 3 mentions for Acrivon Therapeutics and 0 mentions for PHAXIAM Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.95 beat PHAXIAM Therapeutics' score of 0.00 indicating that Acrivon Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Acrivon Therapeutics Positive PHAXIAM Therapeutics Neutral Is ACRV or PHXM more profitable? PHAXIAM Therapeutics' return on equity of 0.00% beat Acrivon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Acrivon TherapeuticsN/A -50.78% -46.08% PHAXIAM Therapeutics N/A N/A N/A Which has more volatility & risk, ACRV or PHXM? Acrivon Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, meaning that its stock price is 135% more volatile than the S&P 500. Which has preferable earnings & valuation, ACRV or PHXM? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcrivon TherapeuticsN/AN/A-$80.56M-$2.25-0.69PHAXIAM TherapeuticsN/AN/A-$240KN/AN/A Do institutionals and insiders hold more shares of ACRV or PHXM? 71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 11.9% of Acrivon Therapeutics shares are owned by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryAcrivon Therapeutics beats PHAXIAM Therapeutics on 8 of the 12 factors compared between the two stocks. Get PHAXIAM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHXM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHXM vs. The Competition Export to ExcelMetricPHAXIAM TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.58M$240.65M$5.78B$10.07BDividend YieldN/A3.78%5.70%4.62%P/E RatioN/A42.2175.3826.21Price / SalesN/A5,025.70472.8192.71Price / CashN/A13.1937.0859.91Price / Book0.3997.3111.906.28Net Income-$240K-$90.99M$3.29B$270.85M7 Day PerformanceN/A2.83%2.13%4.11%1 Month PerformanceN/A21.51%9.08%8.40%1 Year PerformanceN/A573.97%66.35%28.69% PHAXIAM Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049ACRVAcrivon Therapeutics3.5951 of 5 stars$1.33+2.3%$17.57+1,221.2%-81.0%$41.84MN/A-0.5958Short Interest ↓High Trading VolumeOTLKOncobiologics2.2101 of 5 stars$0.94+5.3%$9.60+926.7%-87.2%$41.53MN/A-1.6420Short Interest ↑Gap UpHigh Trading VolumeLVTXLAVA Therapeutics1.983 of 5 stars$1.57+1.3%$2.69+71.0%-7.9%$41.30M$4.99M-1.5060Short Interest ↑GBIOGeneration Bio4.1979 of 5 stars$5.99+3.6%$10.67+78.1%-76.0%$40.37M$19.89M-0.55150Negative NewsShort Interest ↓PLURPluri2.582 of 5 stars$5.10+5.1%$12.00+135.3%-9.7%$40.13M$1.03M-0.92150News CoverageUpcoming EarningsTELOTelomir Pharmaceuticals2.03 of 5 stars$1.24flat$15.00+1,109.7%-78.9%$40.03MN/A-2.301Short Interest ↑XFORX4 Pharmaceuticals4.741 of 5 stars$3.50-3.8%$34.17+876.2%-83.6%$39.94M$2.56M-0.2480Positive NewsShort Interest ↓Gap DownEGRXEagle PharmaceuticalsN/A$3.03-1.3%N/A-16.2%$39.35M$257.55M0.00100Gap DownESLAEstrella Immunopharma2.5168 of 5 stars$1.05-2.8%$16.00+1,423.8%+6.0%$38.92MN/A-4.04N/ANews CoverageGap UpSCYXSCYNEXIS1.2879 of 5 stars$0.89+2.4%N/A-24.1%$37.31M$3.75M-2.2260Positive News Related Companies and Tools Related Companies Acrivon Therapeutics Competitors Oncobiologics Competitors LAVA Therapeutics Competitors Generation Bio Competitors Pluri Competitors Telomir Pharmaceuticals Competitors X4 Pharmaceuticals Competitors Eagle Pharmaceuticals Competitors Estrella Immunopharma Competitors SCYNEXIS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHXM) was last updated on 9/11/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PHAXIAM Therapeutics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share PHAXIAM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHXM Stock Alerts